Skip to main content

Vials

What is a Phase III clinical trial?

A potential hyperimmune treatment for COVID-19 reaches a regulatory milestone in testing its efficacy and safety.

06 Nov 2020 Bern Location
COVID Hyperimmune Production

First Patient Enrolled to Evaluate Potential COVID-19 Hyperimmune Medicine

As co-leader, CSL Behring is very actively involved in this project. The product for the clinical trial phase 3 was manufactu…

09 Oct 2020 Bern Location

Opening of New Manufacturing Facility in Bern

CSL Behring had a small celebration to mark the grand opening of the facility,

08 Oct 2020 Bern Location
Protinus-Batch-Slots

Expansion Nears Completion in Switzerland

CSL Behring validates new production capacity in Bern.

Graphic CSL Full Year Results 2020

CSL Delivers Net Profit of Over $2.1 Billion

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a reported net profit after tax of $2,103 million (1) for the 12 months en…

19 Aug 2020 Bern Location
female scientist injects solution into a test tube

New partner for BaseLaunch

CSL Behring to become latest partner in BaseLaunch Phase II

06 Aug 2020 Company
scientist turns in the lab with her ponytail flying behind her

Careful Steps Into a New Normal

One of CSL Behring's newest innovation centers in Bern, Switzerland, springs back to full life, with COVID-19 precautions in …

15 Jul 2020 Bern Location
plasma-alliance

Bern's contribution against COVID-19

CSL Behring in Bern manufactures the hyperimmune for the pivotal Phase III clinical trial.

10 Jul 2020 Bern Location
covig-alliance-cslbehring

In Fight Against COVID-19

CSL Behring now evaluating 5 approaches to preventing and treating COVID-19.

09 Jul 2020 Bern Location